

CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

SR1017 (CONCENTRATE) // PRODUCED: OCT 06, 2021

CLIENT: CANNEUTICS, LLC // BATCH: PASS



MATRIX: CONCENTRATE
SAMPLE ID: NAL-210930-038
COLLECTED ON: SEP 30, 2021
RECEIVED ON: SEP 30, 2021
BATCH/SAMPLE SIZE: 500 G / 1.4 G
SAMPLED BY: KEVIN P MCALOON
RECEIVED BY: DEVIN DUTRISAC

CANNABINOID OVERVIEW

CBD: 48.8 %
CBC: 2.20 %
TOTAL CANNABINOIDS: 54.5 %

CULTIVATOR INFO

CULTIVATOR
KEVIN MCALOON
10 SUMMER ST
KENNEBUNK, MAINE 04043

LICENSE
CGR26593
MEDICINAL - CAREGIVER

MANUFACTURER INFO

MANUFACTURER
KEVIN MCALOON
10 SUMMER ST
KENNEBUNK, MAINE 04043

LICENSE
CGR26593
MEDICINAL - CAREGIVER

BATCH RESULT: PASS

POTENCY TESTED
METALS PASS
MYCOTOXINS PASS
PESTICIDES PASS
SOLVENTS PASS
TERPENES TESTED

CAN. 1: POTENCY & CANNABINOID PROFILE BY HPLC-UV PREPARATION: OCT 01, 2021 // ANALYSIS: OCT 01, 2021

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBC	2.20 %	22.0 mg/g	22.0 mg/g	0.142/0.708	N/A
CBCA	ND	ND	ND	0.142/0.708	N/A
CBD	48.8 %	488 mg/g	488 mg/g	0.142/0.708	N/A
CBDA	1.97 %	19.7 mg/g	19.7 mg/g	0.142/0.708	N/A
CBDV	< LOQ	< LOQ	< LOQ	0.142/0.708	N/A
CBDVA	ND	ND	ND	0.142/0.708	N/A
CBG	< LOQ	< LOQ	< LOQ	0.142/0.708	N/A
CBGA	ND	ND	ND	0.142/0.708	N/A
CBL	ND	ND	ND	0.142/0.708	N/A
CBLA	ND	ND	ND	0.142/0.708	N/A
CBN	ND	ND	ND	0.142/0.708	N/A

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBNA	ND	ND	ND	0.142/0.708	N/A
Δ ⁸ -THC	ND	ND	ND	0.142/0.708	N/A
Δ ⁹ -THC	1.52 %	15.2 mg/g	15.2 mg/g	0.142/0.708	N/A
Δ ¹⁰ -THC	ND	ND	ND	0.142/0.708	N/A
EXO-THC	ND	ND	ND	0.142/0.708	N/A
THCA	ND	ND	ND	0.142/0.708	N/A
THCV	ND	ND	ND	0.142/0.708	N/A
THCVA	ND	ND	ND	0.142/0.708	N/A
TOTAL THC **	1.52 %	15.2 mg/g	15.2 mg/g		N/A
TOTAL CBD **	50.5 %	505 mg/g	505 mg/g		N/A

** TOTAL THC = (THCA X 0.877) + THC

** TOTAL CBD = (CBDA X 0.877) + CBD

Reported on an as received basis

1000 µg/g = 1 mg/g



RESULTS CERTIFIED BY:
BARRY CHAFFIN
COO, NOVA ANALYTIC LABS
OCT 06, 2021

RESULTS CERTIFIED BY:
GREG NEWLAND
CSO, NOVA ANALYTIC LABS
OCT 06, 2021

RESULTS CERTIFIED BY:
CHRIS ALTOMARE
CEO, NOVA ANALYTIC LABS
OCT 06, 2021

**TERPENES BY HEADSPACE GC-MS
PREPARATION: OCT 01, 2021 // ANALYSIS: OCT 04, 2021**

ANALYTE	AMT	AMT	LOD/LOQ (mg/g)	PASS/FAIL
TOTAL TERPENES	1.11 %	11.1 mg/g		N/A
β-CARYOPHYLLENE	0.541 %	5.41 mg/g	0.0867/0.173	N/A
α-HUMULENE	0.162 %	1.62 mg/g	0.0867/0.173	N/A
α-BISABOLOL	0.0817 %	0.817 mg/g	0.0867/0.173	N/A
TRANS-NEROLIDOL	0.0668 %	0.668 mg/g	0.0867/0.173	N/A
LINALOOL	0.0631 %	0.631 mg/g	0.0867/0.173	N/A
TERPINOLENE	0.0574 %	0.574 mg/g	0.0867/0.173	N/A
β-OCIMENE	0.0491 %	0.491 mg/g	0.0434/0.0867	N/A
β-MYRCENE	0.0437 %	0.437 mg/g	0.0867/0.173	N/A
D-LIMONENE	0.0413 %	0.413 mg/g	0.0867/0.173	N/A
CIS-NEROLIDOL	< LOQ	< LOQ	0.0867/0.173	N/A
CARYOPHYLLENE OXIDE	< LOQ	< LOQ	0.0867/0.173	N/A

ANALYTE	AMT	AMT	LOD/LOQ (mg/g)	PASS/FAIL
α-OCIMENE	< LOQ	< LOQ	0.0434/0.0867	N/A
GERANIOL	ND	ND	0.0867/0.173	N/A
P-CYMENE	ND	ND	0.0867/0.173	N/A
ISOPULEGOL	ND	ND	0.0867/0.173	N/A
α-TERPINENE	ND	ND	0.0867/0.173	N/A
γ-TERPINENE	ND	ND	0.0867/0.173	N/A
EUCALYPTOL	ND	ND	0.0867/0.173	N/A
α-PINENE	ND	ND	0.0867/0.173	N/A
CAMPHENE	ND	ND	0.0867/0.173	N/A
β-PINENE	ND	ND	0.0867/0.173	N/A
Δ ³ -CARENE	ND	ND	0.0867/0.173	N/A

**RSOL.1: RESIDUAL SOLVENTS, POISONS AND TOXINS BY HEADSPACE GC-MS
PREPARATION: OCT 04, 2021 // ANALYSIS: OCT 05, 2021**

ANALYTE	LIMIT	AMT (µg/g)	LOD/LOQ (µg/g)	PASS/FAIL
1,2-DICHLOROETHANE	1 µg/g	ND	0.735/1.47	PASS
ACETONE	5000 µg/g	25.4	7.35/14.7	PASS
ACETONITRILE	410 µg/g	ND	7.35/14.7	PASS
BENZENE	1 µg/g	ND	0.735/1.47	PASS
BUTANE	5000 µg/g	ND	14.7/29.4	PASS
CHLOROFORM	1 µg/g	ND	0.735/1.47	PASS
ETHANOL	5000 µg/g	2170	14.7/29.4	PASS
ETHYL ACETATE	5000 µg/g	< LOQ	14.7/29.4	PASS
ETHYLENE OXIDE	1 µg/g	ND	0.735/1.47	PASS
ETHYL ETHER	5000 µg/g	ND	14.7/29.4	PASS
HEPTANE	5000 µg/g	ND	14.7/29.4	PASS

ANALYTE	LIMIT	AMT (µg/g)	LOD/LOQ (µg/g)	PASS/FAIL
HEXANE	290 µg/g	ND	14.7/29.4	PASS
ISOPROPYL ALCOHOL	5000 µg/g	ND	14.7/29.4	PASS
METHANOL	3000 µg/g	ND	14.7/29.4	PASS
METHYLENE CHLORIDE	1 µg/g	ND	0.735/1.47	PASS
PENTANE	5000 µg/g	ND	14.7/29.4	PASS
PROPANE	5000 µg/g	ND	14.7/29.4	PASS
TOLUENE	890 µg/g	ND	14.7/29.4	PASS
TRICHLOROETHYLENE	1 µg/g	ND	0.735/1.47	PASS
O-XYLENE	2170 µg/g	ND	3.68/7.35	PASS
P- AND M-XYLENE	2170 µg/g	ND	1.47/2.94	PASS
TOTAL XYLENES	2170 µg/g	ND		PASS

**PES.1: PESTICIDES, INSECTICIDES, FUNGICIDES AND GROWTH REGULATORS BY LC-MS/MS
PREPARATION: OCT 01, 2021 // ANALYSIS: OCT 04, 2021**

ANALYTE	LIMIT	AMT (µg/kg)	LOD/LOQ (µg/kg)	PASS/FAIL
BIFENTHRIN	200 µg/kg	ND	60.0/180	PASS
CYFLUTHRIN	1000 µg/kg	ND	300/900	PASS
DAMINOZIDE	1000 µg/kg	ND	300/900	PASS
ETOXAZOLE	200 µg/kg	ND	60.0/180	PASS

ANALYTE	LIMIT	AMT (µg/kg)	LOD/LOQ (µg/kg)	PASS/FAIL
IMAZALIL	200 µg/kg	ND	60.0/180	PASS
MYCLOBUTANIL	200 µg/kg	ND	60.0/180	PASS
SPIROMESIFEN	200 µg/kg	ND	60.0/180	PASS
TRIFLOXYSTROBIN	200 µg/kg	ND	60.0/180	PASS

**MYC.1: MYCOTOXINS BY LC-HRMS
PREPARATION: OCT 05, 2021 // ANALYSIS: OCT 06, 2021**

ANALYTE	LIMIT	AMT (µg/kg)	LOD/LOQ (µg/kg)	PASS/FAIL
AFLATOXIN B1		ND	0.240/0.720	N/A
AFLATOXIN B2		ND	0.720/1.20	N/A
AFLATOXIN G1		ND	0.240/0.720	N/A

ANALYTE	LIMIT	AMT (µg/kg)	LOD/LOQ (µg/kg)	PASS/FAIL
AFLATOXIN G2		ND	0.240/1.20	N/A
OCHRATOXIN A		ND	0.480/1.44	N/A
TOTAL MYCOTOXINS	20 µg/kg	ND		PASS

**HME.1: HEAVY METALS BY ICP-MS
PREPARATION: OCT 01, 2021 // ANALYSIS: OCT 01, 2021**

ANALYTE	LIMIT	AMT (µg/kg)	LOD/LOQ (µg/kg)	PASS/FAIL
ARSENIC	200 µg/kg	ND	47.7/119	PASS
CADMIUM	200 µg/kg	ND	47.7/119	PASS

ANALYTE	LIMIT	AMT (µg/kg)	LOD/LOQ (µg/kg)	PASS/FAIL
LEAD	500 µg/kg	< LOQ	47.7/143	PASS
MERCURY	100 µg/kg	ND	47.7/95.4	PASS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OMP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTE: NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED.

END OF REPORT

